Chuoru Li - Cipher Pharmaceuticals Co Controller
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Insider
Chuoru Li is Co Controller of Cipher Pharmaceuticals
| Phone | 905 602 5840 |
| Web | https://www.cipherpharma.com |
Cipher Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.149 % which means that it generated a profit of $0.149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2403 %, meaning that it generated $0.2403 on every $100 dollars invested by stockholders. Cipher Pharmaceuticals' management efficiency ratios could be used to measure how well Cipher Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Cipher Pharmaceuticals has accumulated 507 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cipher Pharmaceuticals has a current ratio of 2.46, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cipher Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cipher Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cipher Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cipher to invest in growth at high rates of return. When we think about Cipher Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Arvind Utchanah | Knight Therapeutics | N/A | |
| France Landry | Cannara Biotech | N/A | |
| Gilbert Godin | HLS Therapeutics | 64 | |
| Tim MBA | HLS Therapeutics | 51 | |
| Susan Emblem | Knight Therapeutics | N/A | |
| Jeff Martens | Knight Therapeutics | N/A | |
| David Young | Centr Brands Corp | 42 | |
| Dominic KingSmith | Crescita Therapeutics | N/A | |
| Arjan Chima | Centr Brands Corp | 40 | |
| Jody Engel | Knight Therapeutics | N/A | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Sanjiv Sharma | HLS Therapeutics | 67 | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Avi Krivorot | Cannara Biotech | N/A | |
| BA BA | Knight Therapeutics | 53 | |
| Brian Sherman | Cannara Biotech | N/A | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| BA LLB | HLS Therapeutics | 65 | |
| JD BA | HLS Therapeutics | 42 | |
| Leopoldo Bosano | Knight Therapeutics | N/A | |
| Joseph JD | Centr Brands Corp | 56 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 |
Cipher Pharmaceuticals Leadership Team
Elected by the shareholders, the Cipher Pharmaceuticals' board of directors comprises two types of representatives: Cipher Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cipher. The board's role is to monitor Cipher Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cipher Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cipher Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bryan Jacobs, Chief Officer | ||
| Craig Mull, Interim Chairman | ||
| Emilio Presti, Marketing Sales | ||
| Diane Gajewczyk, VP Affairs | ||
| Chuoru Li, Co Controller | ||
| David Miller, Director Fin |
Cipher Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cipher Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |